Mounjaro (tirzepatide) has a strong safety profile for weight loss based on large clinical trials, and the FDA approved it under the brand name Zepbound specifically for chronic weight management in November 2023. That said, it carries real side effects and a few serious warnings worth understanding before you start. Here’s what the evidence shows about both its effectiveness and its risks.
How Mounjaro and Zepbound Differ
Mounjaro and Zepbound contain the exact same active ingredient, tirzepatide. Mounjaro is the brand approved for type 2 diabetes, while Zepbound is the brand approved for weight loss in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition like high blood pressure or high cholesterol. Many people use “Mounjaro” as a catch-all when they’re really talking about tirzepatide for weight loss, but the distinction matters for insurance coverage and prescribing.
How Much Weight People Actually Lose
The landmark SURMOUNT-1 trial followed over 2,500 adults without diabetes for 72 weeks. The results were striking. People on the lowest dose (5 mg) lost an average of 15% of their body weight. The middle dose (10 mg) produced 19.5% loss, and the highest dose (15 mg) led to 20.9% loss. The placebo group lost just 3.1%. For someone weighing 250 pounds, the highest dose translates to roughly 52 pounds lost over about a year and a half.
Common Side Effects
Gut-related side effects are by far the most frequent complaint. In clinical trials, up to 22% of people taking tirzepatide experienced nausea, about 12% to 17% had diarrhea, and up to 10% reported vomiting. These symptoms tend to be worst during the first few weeks and when the dose increases, then gradually improve as your body adjusts.
Higher doses are more likely to cause these problems. The medication starts at a low 2.5 mg weekly dose for the first four weeks specifically to ease your body into it, then increases by 2.5 mg increments every four weeks until you reach a maintenance dose (up to 15 mg). This slow ramp-up is designed to minimize nausea and vomiting, though some people still find the side effects difficult enough to stop treatment. In the SURMOUNT-1 trial, between 4% and 7% of participants on tirzepatide discontinued because of side effects, compared to about 3% on placebo.
Serious Adverse Events
Serious side effects were uncommon in clinical trials, and here’s the reassuring part: they occurred at roughly the same rate in the medication group as in the placebo group. Serious adverse events affected 5.1% to 6.9% of people on tirzepatide across the three dose levels, compared to 6.8% of those on placebo. In other words, the overall rate of serious problems wasn’t meaningfully higher than what you’d see in a similar group of people taking nothing at all.
That said, a few specific serious risks deserve attention:
- Pancreatitis. Acute pancreatitis occurs in roughly 0.39% of users, which is rare but potentially dangerous. One published case report documented a fatal case of severe pancreatitis shortly after starting tirzepatide. If you develop severe, persistent abdominal pain (sometimes radiating to the back), that’s a reason to seek immediate medical attention and stop the medication.
- Gallbladder problems. Rapid weight loss from any cause increases the risk of gallstones, and tirzepatide is no exception. Gallstones and gallbladder inflammation have been reported in trials. Deaths associated with all adverse effects from tirzepatide, including pancreatitis and gallbladder disease, are estimated at less than 1% regardless of dose.
The Thyroid Warning
Mounjaro carries the FDA’s most prominent safety alert, a boxed warning, about thyroid tumors. In rat studies, tirzepatide caused thyroid C-cell tumors at doses relevant to human use, and the risk increased with higher doses and longer treatment. Whether this translates to humans is genuinely unknown. No confirmed link to thyroid cancer in people has been established, but the uncertainty is serious enough that the FDA requires the warning.
Because of this, tirzepatide is completely off-limits if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you’re on the medication, watch for symptoms like a lump in your neck, trouble swallowing, shortness of breath, or persistent hoarseness.
Who Should Not Take It
Beyond the thyroid-related restrictions, tirzepatide should not be used if you have severe gastroparesis, a condition where the stomach empties abnormally slowly. The medication itself slows gastric emptying as part of how it works, so combining it with an already sluggish stomach can worsen symptoms significantly.
People with a history of thyroid cancer or MEN 2 are also excluded. If you have a history of pancreatitis, most prescribers will weigh the risks carefully before starting you on this class of medication.
What the Safety Profile Looks Like Overall
Tirzepatide’s safety record is broadly in line with other medications in the same class, like semaglutide (Wegovy). The most common problems are digestive and tend to improve with time. Serious events are rare and occur at rates similar to placebo. The thyroid warning, while prominent, is based on animal data without confirmed human cases so far.
The practical experience for most people looks like this: some nausea during the early weeks and dose increases, which fades as the body adapts, paired with significant and sustained weight loss over months. The slow dose titration schedule, starting at 2.5 mg and working up over several months, exists specifically to make the transition more tolerable. Most people who start the medication stay on it, though a small percentage find the gastrointestinal effects too disruptive to continue.